Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, May 19, 2026

Astrocytes in Brain Aging and Neurodegeneration: Cellular Mechanisms and Interventional Strategies

You'll have to ask your competent? doctor to get those emerging therapeutic strategies aimed at modulating astrocyte function, so your astrocytes don't deteriorate.

 Astrocytes in Brain Aging and Neurodegeneration: Cellular Mechanisms and Interventional Strategies

s Flávia C. A. Gomes | Isadora Matias Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil Correspondence: Flávia C. A. Gomes (fgomes@icb.ufrj.br) Received: 5 November 2025 | Revised: 20 April 2026 | Accepted: 30 April 2026 Keywords: aging | astrocyte | glial cells | neurodegenerative diseases 

ABSTRACT 


Aging is characterized by progressive changes in the physiology of brain cells, which may contribute to cognitive decline, ultimately leading to dementia and impaired quality of life. The increase in senescent cells, including glial cells in the brain, is a general feature of normal aging and has been associated with age- related pathologies. Although recent evidence suggests that astrocytes undergo senescence in these conditions, little is known about the molecular, and cellular mechanisms under lying this event. This mini review, prepared as part of the special issue Neurochemistry in Latin America, provides a focused overview of astrocyte dysfunction in physiological aging and neurodegenerative conditions, integrating findings from the field alongside recent contributions from our group. We discuss how astrocyte aging contributes to cognitive decline and highlight emerging evidence on how targeting astrocytes, both genetically and pharmacologically, may rescue cognitive decline associated with aging and neurodegenerative diseases. Astrocytes produce several molecules that control synapse formation and function, which are decreased in the aging brain and in Alzheimer's disease models. In this context, recent studies indicate that astrocytes undergo significant molecular and functional remodeling during aging. Notably, astrocyte senescence has been associated with loss of lamin- B1, nuclear alterations, impaired synaptogenic and neuritogenic capacity, altered glutamate metabolism, and mitochondrial dysfunction, all of which may contribute to reduced neuronal support and circuit integrity. In parallel, recent advances have shown that astrocyte responses during aging also include diverse reactive states that vary according to brain region, microenvironment, and disease stage. Importantly, senescence- associated and reactive features are not mutually exclusive and may coexist or interact, further contributing to synaptic dysfunction and increased vulnerability to neurodegeneration. Finally, we discuss emerging therapeutic strategies aimed at modulating astrocyte function, including targeting astrocyte- derived synaptogenic factors and metabolic pathways, as potential approaches to mitigate cognitive decline. Together, current evidence indicates that astrocyte dysfunction in aging reflects a complex and dynamic spectrum of cellular states that play a central role in brain vulnerability and represent promising targets for intervention in aging and neurodegenerative diseases. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2026 The Author(s). Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for

No comments:

Post a Comment